KalVista Pharmaceuticals, Inc. $KALV Shares Bought by Woodline Partners LP

Key Points

• Woodline Partners LP increased its stake in KalVista Pharmaceuticals by 25.5% in Q1, owning 1,617,469 shares valued at approximately $18.67 million.
• KalVista's stock experienced a 1.4% decline, with a recent trading price of $15.39, following a disappointing earnings report that missed analysts' estimates.
• Several analysts have raised their price targets for KalVista, with HC Wainwright increasing its target from $20 to $27, indicating a positive outlook and a "buy" rating.

Woodline Partners LP grew its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 25.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,617,469 shares of the specialty pharmaceutical company's stock after purchasing an additional 329,068 shares during the period. Woodline Partners LP owned about 3.25% of KalVista Pharmaceuticals worth $18,666,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of KALV. Frazier Life Sciences Management L.P. increased its stake in KalVista Pharmaceuticals by 32.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock worth $41,400,000 after purchasing an additional 1,200,000 shares during the period. Stempoint Capital LP bought a new position in shares of KalVista Pharmaceuticals during the 4th quarter worth $8,409,000. Vestal Point Capital LP increased its stake in shares of KalVista Pharmaceuticals by 19.3% during the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after buying an additional 770,000 shares during the period. Parkman Healthcare Partners LLC purchased a new position in shares of KalVista Pharmaceuticals during the first quarter valued at $8,698,000. Finally, Suvretta Capital Management LLC increased its stake in shares of KalVista Pharmaceuticals by 16.6% during the fourth quarter. Suvretta Capital Management LLC now owns 4,913,012 shares of the specialty pharmaceutical company's stock valued at $41,613,000 after buying an additional 701,007 shares during the period.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,942 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $38,893.24. Following the completion of the transaction, the insider directly owned 119,841 shares of the company's stock, valued at approximately $1,584,298.02. The trade was a 2.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 32,979 shares of the business's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total value of $517,440.51. Following the completion of the transaction, the chief executive officer directly owned 369,595 shares of the company's stock, valued at $5,798,945.55. The trade was a 8.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 59,835 shares of company stock valued at $892,350 over the last three months. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

KALV has been the topic of several research reports. HC Wainwright raised their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a research note on Tuesday, July 8th. JMP Securities raised their price target on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a "market outperform" rating in a research note on Friday. Leerink Partners raised their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. Finally, Needham & Company LLC restated a "buy" rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company's stock. According to data from MarketBeat, KalVista Pharmaceuticals has an average rating of "Buy" and an average target price of $26.43.

KalVista Pharmaceuticals Stock Up 2.5%

Shares of KalVista Pharmaceuticals stock traded up $0.34 on Tuesday, reaching $13.96. 155,896 shares of the stock were exchanged, compared to its average volume of 809,886. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $17.28. The firm has a market capitalization of $705.26 million, a price-to-earnings ratio of -3.54 and a beta of -0.10. The business has a 50 day moving average price of $14.11 and a two-hundred day moving average price of $12.84.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its earnings results on Thursday, September 11th. The specialty pharmaceutical company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.21). The company had revenue of $1.43 million during the quarter, compared to analysts' expectations of $1.97 million. Research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).